MedTrace Logo

FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer

NCT00813137 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-12-08

No results posted yet for this study

Summary

FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonged the overall survival, time to progression and improved response rate in metastatic lung cancer in a large phase III clinical trial in china, so we design this trial to evaluate the safty and efficacy of FolFox4 plus Endostar in patients with advanced colorectal cancer

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Folfox4 plus recombinant human endostatin (Endostar)

Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16

Sponsors & Collaborators

  • The Affiliated Changzhou Tumor Hospital of Suzhou University

    collaborator UNKNOWN

  • Simcere Pharmaceutical Co., Ltd

    lead OTHER

Principal Investigators

  • Yang Ling, M.D, Ph.D · The Affiliated Changzhou Tumor Hospital of Suzhou University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00813137 on ClinicalTrials.gov